[Treatment of chronic hepatitis C in HIV coinfection]

MMW Fortschr Med. 2012 May 16:154 Suppl 1:42-4. doi: 10.1007/s15006-012-0626-x.
[Article in German]
No abstract available

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy*
  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / therapeutic use*
  • Comorbidity
  • Drug Therapy, Combination
  • Genotype
  • HIV Infections / drug therapy*
  • Hepacivirus / drug effects
  • Hepacivirus / genetics
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Liver Cirrhosis / drug therapy
  • Oligopeptides / adverse effects
  • Oligopeptides / therapeutic use
  • Proline / adverse effects
  • Proline / analogs & derivatives
  • Proline / therapeutic use
  • Serine Proteinase Inhibitors / adverse effects
  • Serine Proteinase Inhibitors / therapeutic use

Substances

  • Anti-HIV Agents
  • Oligopeptides
  • Serine Proteinase Inhibitors
  • telaprevir
  • N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
  • Proline